Onconetix shareholders approve reverse stock split ratio range 1:10 to 1:150

Onconetix, Inc.

Reverse stock split proposal approved: 11,956,279 For, 4,222,940 Against, 153,929 Abstentions.
Board authorized to select exact ratio (1-for-10 to 1-for-150) anytime within one year of May 30, 2025.
Adjournment proposal also approved: 13,570,278 For, 2,367,590 Against, 395,280 Abstentions.
44,358,422 shares of common stock were outstanding as of the April 14, 2025 record date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.